Company / Operating Income per Share
Janux Therapeutics, Inc. Operating Income per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$2.54
FY2025
5-year range
-$2.54 / -$1.40
FY2021-FY2025
Trend
-38.4%
vs FY2024
Sector context
#128 of 199
Health Care
What the data says
At $-2.54, Janux Therapeutics, Inc.'s operating income per share ranks #128 of 199 in the Health Care sector. Operating Income per Share has declined for 4 consecutive years, from $-1.40 in FY2021 to $-2.54 in FY2025.
Based on SEC 10-K filings.
-2.54 in FY2025.
Declined from $-1.66 to $-2.54 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#128 of 199 in Health CareTop 64% of 199This company -$2.54 Sector average -$3.34
▼
+23.7% above sector average
Key checks
Key Insights
- Janux Therapeutics, Inc.'s operating income per share has declined for 4 consecutive years.
- In FY2025, operating income per share decreased 38.4% year-over-year.
- Ranks #128 out of 199 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.54 | -38.4% |
| FY2024 | -$1.84 | -10.9% |
| FY2023 | -$1.66 | -2.5% |
| FY2022 | -$1.62 | -15.6% |
| FY2021 | -$1.40 | +73.6% |
| FY2020 | -$5.29 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026